Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs

被引:10
|
作者
Zhang, YQ [1 ]
Coogan, PF
Palmer, JR
Strom, BL
Rosenberg, L
机构
[1] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA
[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA
来源
CANCER DETECTION AND PREVENTION | 2006年 / 30卷 / 01期
关键词
non-Hodgkin lymphoma; non-steroidal anti-inflammatory drug; case-control studies; risk factors;
D O I
10.1016/j.cdp.2005.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Risk factors for non-Hodgkin lymphoma (NHL) are largely unknown. Several studies have examined the relation of nonsteroidal anti-inflammatory drug (NSAID) use to the risk of NHL, with inconsistent results. Methods: We examined NSAID use among 529 newly diagnosed NHL cases and 2013 controls interviewed from 1977 to 2002 in our Case-Control Surveillance Study. Results: The odds ratio for NHL among subjects whose regular NSAID use began at least one year prior to hospital admission compared to never users was 0.9 (95% confidence interval (CI): 0.6-1.3). Odds ratios for less than five years, five to less than 10 years, and 10 or more years of regular use were 1.2 (95% CI: 0.8-1.9), 1.0 (95% CI: 0.5-2.1), and 0.4 (95% CI: 0.1-1.0), respectively. The results were similar for regular aspirin use. Conclusion: Our results add to the body of data suggesting that NSAIDs do not increase the risk of NHL and even suggest the possibility of protection by long-term use. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:99 / 101
页数:3
相关论文
共 50 条
  • [41] NON-STEROIDAL ANTI-INFLAMMATORY DRUGS - USE IN RHEUMATIC DISEASES
    HARRIS, DC
    CUMMINGS, NA
    JOURNAL OF THE KENTUCKY MEDICAL ASSOCIATION, 1979, 77 (06): : 285 - 288
  • [42] Non-steroidal anti-inflammatory drugs and the risk of melanoma.
    Jeter, JM
    Bonner, JD
    Johnson, T
    Gruber, SB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 112S - 112S
  • [43] Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs
    Anwar, Asif
    Anwar, Imran John
    Delafontaine, Patrice
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (08) : 726 - 735
  • [44] Pharmacogenetics of non-steroidal anti-inflammatory drugs
    Rollason, V.
    Samer, C.
    Desmeules, J. A.
    DOULEUR ET ANALGESIE, 2013, 26 (04): : 195 - 202
  • [45] Non-steroidal Anti-Inflammatory Drugs and Melanoma
    Sanz-Motilva, Virginia
    Martorell-Calatayud, Antonio
    Nagore, Eduardo
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (26) : 3966 - 3978
  • [46] ASTHMA AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    SZCZEKLIK, A
    GRYGLEWSKI, RJ
    NIZANKOWSKA, E
    ANNALS OF INTERNAL MEDICINE, 1979, 90 (01) : 126 - 127
  • [47] A REVIEW OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    ROSENBLOOM, D
    CRAVEN, MA
    CANADIAN FAMILY PHYSICIAN, 1983, 29 (NOV) : 2121 - 2124
  • [48] Safety of non-steroidal anti-inflammatory drugs
    Weintraub, William S.
    EUROPEAN HEART JOURNAL, 2017, 38 (44) : 3293 - 3295
  • [49] INTERACTIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    TONKIN, AL
    WING, LMH
    BAILLIERES CLINICAL RHEUMATOLOGY, 1988, 2 (02): : 455 - 483
  • [50] NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND CYTOTOXICS
    POWLES, TJ
    MILLAR, JL
    CANCER TREATMENT REVIEWS, 1979, 6 : 63 - 67